STAND NUMBER: 755
My Personal Therapeutics
My Personal Therapeutics provides revolutionary personalised cancer therapeutics.
Personal Discovery Process (PDP)
My Personal Therapeutics offers the most advanced and personalised cancer treatment design, using technology pioneered at the Mount Sinai School of Medicine. Our Personal Discovery Process (PDP) provides individuals with treatment-driven research on an unprecedented scale. PDP is effectively a massive clinical trial for a single patient. We engineer the genetic complexity of each patient`s unique tumour network into an army of 400,000 fruit fly "avatars.` Using robotics, we evaluate up to 1,200 FDA approved drugs including non-cancer drugs, to identify drug combinations that significantly improve mortality in the individual`s avatar population.
The Icahn School of Medicine at Mount Sinai developed the PDP methodology over four years of clinical research, with technical input from the FDA. They found that that real-world patient tumours are made resistant to single drug treatments by mutations in multiple genes, including genes not previously associated with cancer. Such resistant tumours can, however, be effectively addressed with novel combinations of FDA approved drugs. The most effective combinations almost always include non-cancer drugs. The PDP methods are licensed exclusively to My Personal Therapeutics.
PDP first identifies all gene mutations associated with the patient`s tumour via DNA sequencing. DNA can be extracted from either a new biopsy or from a previous histologic sample used for diagnosis.
Then, this complex oncogenetic network is modelled in the intestine of the fruit fly, Drosophila melanogaster, to generate a personalised fly avatar that carries the patient cancer. Up to 400,000 avatar flies are grown for each patient and used to screen ~1800 drugs and drug combinations covering the full FDA library of approved compounds. PDP can take 3 - 5 months after tumour and blood sequencing results are available. The difference in time reflects differences in tumour type, complexity, the number of drugs and drug combinations tested until the final cocktail is identified.
What is the rationale for using flies to find the most appropriate personalised therapy? Drosophila is the most flexible genetic model organism. The unique genetic toolkit available in flies enables us to introduce up to 20 gene mutations found in the patient`s tumour, allowing the creation of a fully personalised avatar carrying a tumour `à la carte`. The small size and the short life cycle of these animals permits the fast expansion of the avatar population. In this way, we create and utilise 400K flies (an impossible number for any other animal model) to run a high-throughput drug screening, allowing us to generate powerful pre-clinical statistics for every drug or drug combination tested. Functional exploration of colorectal cancer genomes using Drosophila (Cagan Lab Publication)
How does PDP compare to targeted therapies?
Targeted therapies are designed to specifically hit target mutations present in the patient`s tumour and as such represents an improvement of traditional chemotherapy. This approach would work well in cases where a single actionable target gene is identified (e.g. BRAF), for which a drug has been developed (e.g. VEMURAF). However, almost every tumour will show several actionable mutated genes, e.g. BRAF + APC + EGFR + PTEN. Taking one drug for every target is not possible because of the high toxicity produced by the combination of anti-cancer drugs. Thus, the oncologist is forced to choose from one of these mutations and select a targeted therapy based on partial genetic information, leading to failed treatments and tumour resistance.
PDP can introduce up to 20 cancer associated mutations per avatar and find the drug cocktails that target the oncogenic network created by them. Thus, the treatment recommendation is developed based on a comprehensive mutational cancer landscape. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology (Cagan Lab Publication)
Why is PDP better than other personalised options?
PDP is the world`s only strategy using real patients` avatars for drug screenings. Genetic mouse avatars cannot be created due to lack of sophisticated genetic tools - only two or three mutations could be introduced in mice, not comparable to the 20 mutations included in the PDP model.
Related options include patient-derived xenograft (PDX) mice and organoids. Although initially promising, the implementation of PDX mice for the identification of personalised treatments has been halted due to lack of success and cost constraints, and they are currently used for academic research only.
Cell-based strategies such as organoids built from a patient`s cancer cells are available. However, organoids can be obtained for only a fraction of patients and they are used to test standard of care medicines. Moreover, as these cancer cells are artificially cultured, they lack real drug response because they are acting in an in vitro artificial environment.
Therefore, MPT's` technology is positioned at the forefront of personalised medicine.
Who can benefit from PDP?
PDP can be employed for patients with gastro-intestinal (GI) cancers, including tumours of the upper (e.g. oesophagus) and lower (e.g. colorectal) GI tract, as well as for patients with lung cancers. Patients with rare cancers or tumours of unknown origin for which no standard protocol has been established could also greatly benefit from PDP.
PDP can help identify optimal treatments for patients with early cancers as well as for patients with difficult to treat advanced cancers, who have exhausted treatment options with conventional approaches. Finally, people with pre-malignant gut lesions can also benefit from PDP. The presence of adenomas in the digestive tract is well correlated with the development of a colorectal cancer in the following years. Non cancer patients with this feature can greatly benefit from having a pre-avatar model already built and ready to provide a treatment recommendation when required. A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer
+44203 923 3300